Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

Rakesh Jain,¹ Hemangi R. Panchmatia,² Alejandro G. Hughes,³ Noah S. Webb,³ Michael J. Doane,² Andrew J. Cutler^{4,5}

¹Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX; ²Alkermes, Inc., Waltham, MA; ³Optum, Inc., Eden Prairie, MN; ⁴SUNY Upstate Medical University, Syracuse, NY; ⁵Neuroscience Education Institute, Lakewood Ranch, FL

INTRODUCTION

- Long-term pharmacotherapy with antipsychotic medication is recommended for treating schizophrenia (SZ) and bipolar I disorder (BD-I)^{1,2}
- However, adverse effects of atypical antipsychotics, including weight gain, contribute to nonadherence and treatment discontinuation,³ potentially leading to hospitalization and other healthcare resource utilization (HCRU)^{4,5}
- The combination of olanzapine and samidorphan (OLZ/SAM) was developed to provide the established antipsychotic efficacy of olanzapine⁶ while mitigating olanzapine-associated weight gain⁷; several clinical trials have provided evidence of these effects⁸⁻¹⁰
- Until now, no real-world studies have examined HCRU among patients with SZ or BD-I who have initiated treatment with OLZ/SAM
- This analysis aimed to understand if OLZ/SAM may be associated with reductions in HCRU in patients in a real-world

OBJECTIVE

To assess and compare HCRU 6 months before and after initiating OLZ/SAM in patients treated for SZ or BD-I

METHODS

Data Source

• This retrospective study used administrative claims data from April 19, 2021, through December 31, 2022 (study period), obtained from Komodo Healthcare Map, a fully deidentified US-based database containing detailed information on inpatient (IP), outpatient (OP), and pharmacy claims data from ~150 million patients covered by commercial (66%), Medicaid (27%), or Medicare Advantage (7%) plans

Patients and Study Design


Inclusion Criteria

- Adults (aged ≥18 years) with ≥1 medical claim for SZ or BD-I (Figure 1)
- ≥1 pharmacy or medical claim for OLZ/SAM
- ≥6 months of continuous enrollment with medical and pharmacy benefits before (baseline period) and after (fixed follow-up period) the index date (date of first medical or pharmacy claim for OLZ/SAM)
- ≥1 medical claim for SZ or BD-I during the baseline or follow-up period
- Patients with medical claims for both SZ and BD-I were assigned an indication of SZ

Exclusion Criteria

Patients with pharmacy or medical claims for OLZ/SAM during the baseline period

Figure 1. Study Design



OLZ/SAM, combination olanzapine and samidorphan

Outcomes

- HCRU, including IP admissions (with length of stay [LOS]) and emergency department (ED) and OP visits in each of the following categories:
- All-cause HCRU
- Mental health-related HCRU
- Baseline demographics, clinical characteristics (including comorbidities), and medication use

Statistics

- For baseline patient demographics and clinical characteristics, numbers and percentages were reported for categorical variables, and means and SDs were reported for continuous variables
- Six-month pre-post comparisons (baseline vs follow-up) were made using the following unadjusted pairwise comparisons:
- Paired t-test for normally distributed continuous variables
- Wilcoxon signed-rank test for distribution-free continuous variables


McNemar test for dichotomous variables

RESULTS

Patients

• The analysis included data from 855 patients with SZ and 691 with BD-I (Figure 2; Table 1 and Table 2)

Figure 2. Patient Identification



^aPatients with medical claims for both SZ and BD-I were assigned an indication of SZ (n=129); patients with pharmacy or medical claims for the index med BD-I. bipolar I disorder: ICD-10-CM. International Classification of Diseases, 10th Revision, Clinical Modification; OLZ/SAM, combination olanzapine and samidorphan; SZ, schizophrenia.

Table 1. Baseline Patient Demographics

Characteristics	SZ Cohort (n=855)	BD-I Cohort (n=691)
Age, mean (SD), years	39.4 (13.6)	38.4 (12.0)
Sex, n (%)		
Female	405 (47.4)	477 (69.0)
Male	450 (52.6)	214 (31.0)
Region, n (%)		
South	243 (28.4)	212 (30.7)
Midwest	240 (28.1)	224 (32.4)
West	215 (25.1)	124 (18.0)
Northeast	97 (11.3)	97 (14.0)
Other ^a	60 (7.0)	34 (4.9)
Insurance type, n (%)		
Medicaid	549 (64.2)	354 (51.2)
Medicare	114 (13.3)	48 (7.0)
Multiple	105 (12.3)	73 (10.6)
Commercial	85 (9.9)	213 (30.8)
Unknown	2 (0.2)	3 (0.4)
Index year, n (%)		
2021	200 (23.4)	169 (24.5)
2022	655 (76.6)	522 (75.5)

Islands, Commonwealth of the Northern Mariana Islands, Puerto Rico, Palau, and Virgin Islands. BD-I, bipolar I disorder; SZ, schizophrenia

Table 2. Baseline Clinical Characteristics


Characteristics	SZ Cohort (n=855)	BD-I Cohort (n=691)
Comorbidities reported by ≥10% of patients, n (%)		
Anxiety disorders	367 (42.9)	450 (65.1)
Hypertension	284 (33.2)	196 (28.4)
Obesity	262 (30.6)	204 (29.5)
Any substance use disorder	261 (30.5)	223 (32.3)
Major depressive disorder	258 (30.2)	254 (36.8)
Hyperlipidemia	255 (29.8)	167 (24.2)
Last antipsychotic use before index date, n (%)		
Any second-generation oral ^a	691 (80.8)	578 (83.6)
Any second-generation LAI	70 (8.2)	22 (3.2)
Any first-generation oral	55 (6.4)	19 (2.7)
Any first-generation LAI	15 (1.8)	1 (0.1)
None	47 (5.5)	78 (11.3)
Other common medications ^b taken during baseline period, n (%)		
Antidepressants	553 (64.7)	470 (68.0)
Mood stabilizers	410 (48.0)	490 (70.9)
Antihypertensives	390 (45.6)	321 (46.5)
Anxiolytics	346 (40.5)	356 (51.5)
Metformin	144 (16.8)	97 (14.0)
Patients with type 2 DM	100 (69.4)	49 (50.5)
Patients without type 2 DM	44 (30.6)	48 (49.5)

^aOlanzapine was used by 50% of patients with SZ and 45% of those with BD-I; quetiapine was used by 9% of patients with SZ and 11% of those with BD-I. ^bTaken by ≥30% in any cohort. BD-I, bipolar I disorder; DM, diabetes mellitus; LAI, long-acting injectable; SZ, schizophrenia.

HCRU in SZ Cohort


- Significant reductions from baseline in the proportions of patients with all-cause (Figure 3) and mental health-related (Figure 4) IP admissions and ED visits were observed in the 6 months after OLZ/SAM initiation - Average all-cause IP LOS decreased from 5.9 to 4.8 days (P=0.075)
- Average mental health-related IP LOS decreased from 5.7 days to 4.5 days (P=0.056)

Figure 3. All-Cause HCRU: Schizophrenia Cohort (n=855)^a



ED. emergency department: HCRU. healthcare resource utilization: IP. inpatient; OLZ/SAM, combination olanzapine and samidorphan; OP, outpatient; SZ, schizophrenia

Figure 4. Mental Health—Related HCRU: Schizophrenia Cohort (n=855)^a



ED, emergency department; HCRU, healthcare resource utilization; IP, inpatient; OLZ/SAM, combination olanzapine and samidorphan; OP, outpatient; SZ, schizophrenia


LIMITATIONS

- Results from the insured population studied may not be generalizable to uninsured populations
- A claim for a filled prescription may not indicate that the medication was consumed or taken as prescribed
- The presence of a diagnosis code may not definitively be indicative of disease presence or causality, nor does the presence of a claim indicate disease severity
- Because of the limited follow-up time, HCRU reported may not fully capture the effects of longer-term OLZ/SAM use

HCRU in BD-I Cohort


- Significant reductions from baseline in the proportions of patients with all-cause (Figure 5) and mental health related (Figure 6) IP admissions and ED visits were observed in the 6 months after OLZ/SAM initiation
- Average all-cause IP LOS decreased from 3.4 to 2.2 days (P=0.011)
- Average mental health-related IP LOS decreased from 3.3 to 2.0 days (P=0.007)

Figure 5. All-Cause HCRU: Bipolar I Disorder Cohort (n=691)^a



BD-I, bipolar I disorder; ED, emergency department; HCRU, healthcare resource utilization; IP, inpatient; OLZ/SAM, combination olanzapine and samidorphan; OP, outpatient

Figure 6. Mental Health—Related HCRU: Bipolar I Disorder Cohort (n=691)^a



BD-I, bipolar I disorder; ED, emergency department; HCRU, healthcare resource utilization; IP, inpatient; OLZ/SAM, combination olanzapine and samidorphan; OP, outpatient

CONCLUSIONS

- In this first real-world data assessment of HCRU use in patients with SZ or BD-I, OLZ/SAM initiation was associated with significant reductions in HCRU rates for IP admissions and ED visits
- The proportions of patients with all-cause and mental health—related IP admissions and ED visits decreased significantly between baseline and follow-up periods in patients with SZ and in those with BD-I
- Average IP LOS was reduced between the baseline and follow-up periods by >1 day in both the SZ and BD-I cohorts; reductions were statistically significant in patients with BD-I for both all-cause and mental health-related admissions
- Overall, findings indicate that use of OLZ/SAM may result in clinically meaningful reductions in patient and provider burden, as evidenced by changes in IP care and ED visits



References, acknowledgments, disclosure information, and copies of this poster can be obtained through this QR (Quick Response) code. These materials are for personal use only and may not be reproduced without permission of Alkermes. For permission, contact <u>USMed</u>

Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

Rakesh Jain,¹ Hemangi R. Panchmatia,² Alejandro G. Hughes,³ Noah S. Webb,³ Michael J. Doane,² Andrew J. Cutler^{4,5}

¹Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX; ²Alkermes, Inc., Waltham, MA; ³Optum, Inc., Eden Prairie, MN; ⁴SUNY Upstate Medical University, Syracuse, NY; ⁵Neuroscience Education Institute, Lakewood Ranch, FL

REFERENCES

- 1. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Association; 2021.
- 2. Yatham LN, et al. *Bipolar Disord*. 2018;20(2):97-170. DOI: 10.1111/bdi.12609.
- 3. Bessonova L, et al. *BMC Psychiatry*. 2020;20(1):354. DOI: <u>10.1186/s12888-020-02767-x</u>.
- 4. Law MR, et al. *J Clin Psychiatry*. 2008;69(1):47-53. DOI: <u>10.4088/jcp.v69n0107</u>.
- 5. Perkins AJ, et al. *BMC Psychiatry*. 2023;23(1):64. DOI: <u>10.1186/s12888-023-04558-6</u>.
- 6. Leucht S, et al. *Lancet*. 2013;382(9896):951-62. DOI: <u>10.1016/s0140-6736(13)60733-3</u>.
- 7. De Hert M, et al. *Nat Rev Endocrinol*. 2012;8(2):114-26. DOI: <u>10.1038/nrendo.2011.156</u>.
- 8. Martin WF, et al. *Am J Psychiatry*. 2019;176(6):457-67. DOI: <u>10.1176/appi.ajp.2018.18030280</u>.
- 9. Correll CU, et al. *Am J Psychiatry*. 2020;177(12):1168-78. DOI: 10.1176/appi.ajp.2020.19121279.
- 10. Kahn RS, et al. *J Clin Psychiatry*. 2023;84(3):22m14674. DOI: <u>10.4088/JCP.22m14674</u>.

AUTHOR DISCLOSURES

RJ has served as a consultant for AbbVie, Acadia, Adamas, Alfasigma, Alkermes, Almatica, Axsome, Biogen, Boehringer Ingelheim, Cingulate Therapeutics, Corium, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva, Transcend Therapeutics, and Viatris; has received speaker/promotional honoraria from AbbVie, Alkermes, Almatica, Axsome, Corium, Eisai, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Tris Pharmaceuticals, and Viatris; has served on advisory boards for Adamas, Alkermes, Corium, Eisai, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, and Teva; and has received research funding from AbbVie, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda. HRP and MJD are or were employees of Alkermes, Inc., and may own stock/options in the company. AGH and NSW are employees of Optum, Inc., a health services innovation company that received funding from Alkermes, Inc., to conduct this study and analyze the data used for this publication. AJC has served on advisory boards for Alkermes, Acadia, Biogen, BioXcel, Intra-Cellular Therapies, and Teva and on speakers bureaus for Acadia, Axsome, BioXcel, Intra-Cellular Therapies, Neurocrine, and Teva.

ACKNOWLEDGMENTS

This study was sponsored by Alkermes, Inc. (Waltham, MA, USA). Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.